About this trial
The goal of this clinical trial is to identify the most effective way to take acid-blocking medications to treat stomach ulcers in patients who have undergone gastric bypass surgery. The main questions it aims to answer are:
* is taking an acid-blocking medication by opening the capsule and only taking the contents of the capsule (open-capsule) more or less effective than taking the capsule as a whole (intact-capsule) for treating ulcers in patients who have a history of gastric bypass surgery? * does taking the open versus intact medication decrease the number of procedures and complications from untreated ulcers?
Participants with ulcers will be instructed to take acid-blocking medications (called proton-pump inhibitors) either by opening the capsule and taking only the contents or by taking the capsule whole. These medications are the gold standard for treatment of stomach ulcers. Participants will be asked to undergo an upper endoscopy (EGD) every 3 months to monitor the healing of the ulcers.
Researchers will compare how quickly the ulcers heal depending on which way the medications are taken (opened up or as a whole).
Eligibility criteria
Qualifiers
Subjects diagnosed with marginal ulceration post-gastric bypass on upper endoscopy
Disqualifiers
Refusal to start PPI medication OR current open-capsule PPI use at the time of diagnosis of the marginal ulcer
Trial design
Treatments tested in this trial
- Omeprazole 40 milligrams
Treatment groups
Sponsors and collaborators
Stephen Firkins
Lead sponsor
The Cleveland Clinic
Sponsor institution